LightDark Log in Sign up

‹ Back to screener

LAURUSLABS.NS Laurus Labs Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2025-08-21 ₹889.90
2026-08-21 ₹1795.70
Change over window +101.79%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 59.1%
Trailing 20-day average 57.4%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 2231476 1319114 59.11%
2026-08-27 4249869 2755640 64.84%
2026-08-26 3334188 2054289 61.61%
2026-08-25 3550945 1775692 50.01%
2026-08-24 2894242 2236577 77.28%
2026-08-21 1401995 862995 61.55%
2026-08-20 1315065 779825 59.30%
2026-08-19 1426377 794354 55.69%
2026-08-18 1291914 839918 65.01%
2026-08-17 1631767 813401 49.85%
2026-08-14 1581352 749282 47.38%
2026-08-13 1345856 688149 51.13%
2026-08-12 1088545 535800 49.22%
2026-08-11 1514239 841243 55.56%
2026-08-10 1386592 682894 49.25%
2026-08-07 1553067 1054791 67.92%
2026-08-06 2037418 1338093 65.68%
2026-08-05 2090998 1173732 56.13%
2026-08-04 1405192 815267 58.02%
2026-08-03 1919384 836420 43.58%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers LAURUSLABS.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
10 Dec 2024 PRATHIMA CHAVA - Pledge Pledge Creation 200000 115280000 0.08% XBRL
30 Oct 2023 G. SREELAKSHMI Immediate relative Sell Market Sale 10000 3760000 0.00% XBRL
24 Mar 2022 Venkata Jayasree Kumari Tadikonda Immediate relative Buy Market Purchase 2906 1681702 0.00% XBRL
24 Mar 2022 Venkata Jayasree Kumari Tadikonda Immediate relative Buy Market Purchase 3992 2310170 0.00% XBRL
24 Mar 2022 Venkata Jayasree Kumari Tadikonda Immediate relative Buy Market Purchase 788 456016 0.00% XBRL
01 Mar 2022 MADHURI MEDASANI Immediate relative Buy Market Purchase 10000 5396671 0.00% XBRL
01 Mar 2022 YAMINI TANGUTURI Immediate relative Sell Market Sale 2275 1196525 0.00% XBRL
18 Dec 2021 Chandra kumari Immediate relative Pledge Pledge Creation 10245 5173725 0.00% XBRL
20 Sep 2021 VIJAYA KUMARI SURYADEVARA Immediate relative Sell Market Sale 12000 7895000 0.02% XBRL
09 Sep 2021 SREELAKSHMI GOGIREDDY Immediate relative Sell Market Sale 1000 650000 0.01% XBRL
09 Sep 2021 SREELAKSHMI GOGIREDDY Immediate relative Sell Market Sale 4000 2603600 0.01% XBRL
02 Sep 2021 YALAMANCHI RAMA Immediate relative Sell Market Sale 5500 3613500 0.00% XBRL
13 Aug 2021 S ANIL KUMAR REDDY Employees/Designated Employees Sell Market Sale 3000 2009293 0.00% XBRL
13 Aug 2021 SRINIVASA RAO SURYADEVARA Employees/Designated Employees Sell Market Sale 18120 12743294 0.17% XBRL
13 Aug 2021 SRINIVASA RAO SURYADEVARA Employees/Designated Employees Sell Market Sale 67657 47555590 0.15% XBRL
13 Aug 2021 SRINIVASA RAO SURYADEVARA Employees/Designated Employees Sell Market Sale 20000 14000000 0.10% XBRL
11 Aug 2021 MADHUVEER YADAVALLI Employees/Designated Employees Sell Market Sale 1445 1012944 0.00% XBRL
07 Jul 2021 K GIRISH Employees/Designated Employees Sell Market Sale 15000 10215000 0.03% XBRL
07 Jul 2021 N L NARASIMHA RAO Employees/Designated Employees Pledge Pledge Creation 5060 3484569 0.00% XBRL
07 Jul 2021 N L NARASIMHA RAO Employees/Designated Employees Buy Market Purchase 2910 2003972 0.00% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers LAURUSLABS.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹1802.00 INR (live) · fetched 2026-08-23 23:35 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
109.45
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹1,802.00 / (₹8,887,900,000 / 539,850,000 shares) = ₹1,802.00 / ₹16.46 EPS
FY2025-26 · Annual filing
ROE
16.77%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹8,887,900,000 / ₹53,000,600,000 = 16.77%
FY2025-26 · Annual filing
Debt/Equity
0.45
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹23,974,900,000 / ₹53,000,600,000 = 0.45
FY2025-26 · Annual filing
Current Ratio
1.33
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹48,292,100,000 / ₹36,354,300,000 = 1.33
FY2025-26 · Annual filing
ROCE
17.57%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹13,526,100,000 / (₹53,000,600,000 + ₹23,974,900,000) = 17.57%
FY2025-26 · Annual filing
Dividend Yield
0.09%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹863,300,000 / 539,850,000 shares) / ₹1,802.00 = ₹1.60 / ₹1,802.00
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 4.1%
Net Profit (3y) 4.0%
Revenue (5y, 3.0y actual) 4.1%
Net Profit (5y) 4.0%
Revenue (10y, 3.0y actual) 4.1%
Net Profit (10y) 4.0%

Operating Margin Trend

Eroding

FY2022-23 21.1%
FY2023-24 8.3%
FY2024-25 12.6%
FY2025-26 19.9%

ROCE Trajectory

FY2022-23 21.2%
FY2023-24 6.3%
FY2024-25 9.6%
FY2025-26 17.3%

Earnings Quality

No persistent gap detected

Net Profit CAGR 4.00% vs CFO CAGR 17.77% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit +148.04% vs CFO +169.84%

Sector-Relative Percentile (Healthcare)

ROE 63th
ROCE 52th
Debt/Equity 15th
P/E 9th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q3 FY2023-24 Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹1,194.92 Cr. ₹1,439.67 Cr. ₹1,194.91 Cr. ₹1,223.70 Cr. ₹1,415.05 Cr. ₹1,720.30 Cr. ₹1,569.57 Cr. ₹1,778.29 Cr. ₹1,811.57 Cr. ₹2,026.31 Cr. RevenueFromOperations
Net Profit ₹23.14 Cr. incl. minority ₹23.34 Cr. ₹75.61 Cr. incl. minority ₹75.02 Cr. ₹12.51 Cr. incl. minority ₹12.68 Cr. ₹19.84 Cr. incl. minority ₹19.95 Cr. ₹92.30 Cr. incl. minority ₹92.94 Cr. ₹233.67 Cr. incl. minority ₹232.77 Cr. ₹163.02 Cr. incl. minority ₹161.68 Cr. ₹251.66 Cr. incl. minority ₹251.88 Cr. ₹279.14 Cr. incl. minority ₹282.09 Cr. ₹367.60 Cr. incl. minority ₹362.07 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers LAURUSLABS.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent8887900000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital539850000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets48292100000.0
CurrentLiabilities36354300000.0
EquityAttributableToOwnersOfParent53000600000.0
BorrowingsCurrent + BorrowingsNoncurrent23974900000.0

My notes